West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance
On Thursday, West Pharmaceutical Services, Inc. WST reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72.
West Pharmaceutical forecasts 2025 results below expectations, shares drop
West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels, sending its shares down 18% premarket.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.83 per share a year ago.
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
LH vs. WST: Which Stock Is the Better Value Option?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Thomas DeBourcy - Nephron Research Operator Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call.
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago.
